AzTrials
AzTrials

Venous CongestionVEXUS-REANCT07438015

VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit

A study testing Venous ultrasound (inferior vena cava, portal vein, suprahepatic vein, and renal vein to calculate the VEXUS score ; femoral vein and popliteal vein) in people with Venous Congestion, run by Centre Hospitalier Universitaire de Besancon at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Shock is a common and serious cause of admission to intensive care. Vascular filling is one of the cornerstones of shock treatment, aimed at increasing cardiac output and restoring adequate organ perfusion through rapid intravenous administration of a solution. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Venous Congestion
What is being tested?
Venous ultrasound (inferior vena cava, portal vein, suprahepatic vein, and renal vein to calculate the VEXUS score ; femoral vein and popliteal vein)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
525 participants
Where
1 siteFrance
Study dates
12 Mar 2026to 12 Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients admitted to medical intensive care at Besançon Teaching Hospital for any reason.
  • Aged over 18.
  • Affiliated with a French social security scheme or beneficiary of such a scheme.
  • No objection to participating in the study.
  • Non-inclusion criteria :
  • Minors
Show all 10Show fewer
  • Pregnant women and breastfeeding mothers
  • Persons deprived of their liberty by judicial or administrative decision; persons undergoing compulsory psychiatric treatment; persons admitted to a health or social care institution for purposes other than research
  • Adults subject to legal protection measures or unable to give their consent
  • Subjects who are excluded from another study or listed in the 'national volunteer registry'.

Who cannot join

  • Portal vein, suprahepatic or femoral vein thrombosis at the time of ultrasound examination.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Hadrien WINISZEWSKI, MCU-PH contact

0033381668127

hwiniszewski@chu-besancon.fr

Valentin LAFAY, PHC contact

0033381668127

vlafay@chu-besancon.fr

France1 site, 1 recruiting
  • Centre Hospitalier Universitaire Jean MINJOZ

    Besançon, 25000

    Hadrien WINISZEWSKI, MCU-PH, 0033381668127, hwiniszewski@chu-besancon.fr

    Valentin LAFAY, PHC, 0033381668127, vlafay@chu-besancon.fr

    Recruiting

Other trials in France

About this study

Shock is a common and serious cause of admission to intensive care. Vascular filling is one of the cornerstones of shock treatment, aimed at increasing cardiac output and restoring adequate organ perfusion through rapid intravenous administration of a solution. However, this vascular filling can be accompanied by venous congestion, which can be harmful. Fluid administration must therefore be sparing and carefully considered.

However, it is difficult to assess the correct amount of intravenous fluid to inject. Multi-site venous ultrasound (inferior vena cava, suprahepatic vein, portal vein, renal vein), recently published under a score called VExUS, could be a useful bedside tool for documenting venous congestion and avoiding excessive vascular filling. Nevertheless, this tool has been little evaluated in the general intensive care population, particularly in patients with acute respiratory distress syndrome (ARDS). Its link with other venous sites (femoral, popliteal) has also been little studied to date.

Read more

The main objective of our study is to describe the distribution of the VEXUS score among patients in a general intensive care unit.

The secondary objectives are:

  • To study the feasibility of measuring the VEXUS score in patients with ARDS, including during prone positioning, a recommended and frequently used treatment for this condition, which could make it difficult to acquire venous ultrasound data.
  • In this case, other more accessible venous flows could be analysed, namely the femoral venous flow and the popliteal venous flow. We will therefore also study their feasibility during prone positioning sessions.
  • Subsequently, we will study the correspondence between the VEXUS score and these other types of venous flow (femoral, popliteal).
  • Finally, we will evaluate the association between the VEXUS score in our general intensive care population and the long-term prognosis of patients, in this case death on day 28 and the occurrence of acute renal failure requiring renal replacement therapy during the intensive care stay.
Read the detailed description
  1. SCIENTIFIC JUSTIFICATION FOR THE RESEARCH :
  2. SUMMARY OF CLINICAL AND NON-CLINICAL TRIAL RESULTS :

Shock is a common cause of admission to intensive care:

By causing hypoperfusion of vital organs (kidneys, liver, digestive tract, heart), it can lead to multiple organ failure and death. There are many causes of shock, the main one being severe infection, with approximately 49 million cases worldwide each year and approximately 11 million deaths attributable to shock each year.

Vascular filling is necessary to treat shock:

The first treatment for shock is vascular filling, which consists of the intravenous administration of an isotonic solution over a short period of time. In septic shock, international guidelines recommend injection of 30 mL/kg of fluids as early as possible within the first three hours. The aim of vascular filling is to increase left ventricular systolic ejection volume, and therefore cardiac output and organ perfusion.

Excessive vascular filling is harmful:

However, vascular filling carries a risk of congestion of the venous system. This congestive state has potentially harmful adverse effects, which are now well established: intracranial hypertension and delirium, difficulties in weaning from mechanical ventilation and excess mortality in acute respiratory distress syndrome, acute renal failure, acute congestive hepatitis, intra-abdominal hypertension, decreased intestinal motility or risk of digestive ischaemia and bacterial translocation. Cardiac effects are also plausible. This explains the now well-established statistical link between positive fluid balance and excess mortality.

Fluid administration must therefore be carefully considered and sparing. With this in mind, several authors have recently proposed a concept known as R.O.S.E., which divides resuscitation into four distinct phases: a Resuscitation phase, during which vascular filling is undoubtedly necessary; an Optimisation phase, followed by a Stabilisation phase, during which fluid administration must be adjusted to maintain adequate organ perfusion while avoiding fluid overload, and a final Evacuation phase, during which any excess fluid must be eliminated through the use of diuretics or dialysis. In other words, it is a matter of finding the right window between administering an antidote and poison, to paraphrase Paracelsus. The 2021 guidelines of the Surviving Sepsis Campaign have taken this on board, suggesting that 'to avoid over- and under-resuscitation, fluid administration beyond the initial resuscitation phase should be guided by careful monitoring of volume status and organ perfusion'.

Assessing the correct amount of vascular filling to administer is difficult Multiple tests, whether static (pulse pressure variation, etc.) or dynamic (passive leg raise test), invasive (continuous cardiac output measurement) or non-invasive (echocardiography), are currently available and their results can guide the decision on whether or not to continue vascular filling. However, while this assessment is essential, it is not sufficient on its own, as congestive heart failure can coexist with preload dependence, as demonstrated in a recent study.

Venous ultrasound can detect excess vascular filling Venous congestion should therefore be assessed at the same time. As before, a wide range of tools are available for this purpose, each with its own advantages and limitations. Clinicians can take into account recent medical history, weight gain, clinical detection of oedema in the lower parts of the body, invasive measurement of central venous pressure, echocardiographic measurements, blood biomarkers, and radiological imaging of the lungs. These investigations, which are sometimes tedious, invasive, and non-dynamic, have led to the development of other tools for measuring venous congestion, such as ultrasound of the main veins: the inferior vena cava, to which the suprahepatic veins (and the portal venous system via the liver) and renal veins are connected, and the femoral veins, among others. Preliminary work has already established a link between specific patterns of these venous flows and a congestive state.

The value of venous ultrasound in detecting excessive vascular filling has been little evaluated in the general intensive care population, particularly in patients with acute respiratory distress syndrome The most comprehensive study to date combined several of these patterns (inferior vena cava, suprahepatic vein, portal vein, and renal vein) into a single score, called VEXUS (Venous EXcess Ultrasound Grading System), graded from 0 to 3. A high score was significantly associated with an increased risk of acute renal failure in the cardiac surgery population analysed. Similar results were observed after acute coronary syndrome. A single small study was conducted in the general intensive care population. This study did not specifically evaluate VEXUS in patients with acute respiratory distress syndrome (ARDS), a condition frequently encountered in intensive care. ARDS has several specific characteristics that warrant analysis of venous congestion. On the one hand, pulmonary injury warrants early detection and treatment of congestive state, a recognised risk factor for respiratory deterioration and excess mortality. On the other hand, hypoxaemia and its treatment with high-pressure positive pressure ventilation can cause acute right heart failure, worsening venous congestion. Finally, in cases of refractory hypoxaemia, prone positioning is recommended by the European Society of Intensive Care Medicine following the publication of the French PROSEVA study. The feasibility of measuring venous congestion using VEXUS in the prone position has not been evaluated. Analysis of femoral venous flow or even popliteal venous flow could be useful in this situation.

............................................................................................................................................................................................................................................................................2) SUMMARY OF EXPECTED AND KNOWN BENEFITS AND RISKS : The research procedure consists of an abdominal venous ultrasound (inferior vena cava, portal vein, suprahepatic vein and renal vein) to calculate the VEXUS score, and a venous ultrasound of the lower limbs (femoral vein and popliteal vein). This procedure will be performed at the same time as the cardiac ultrasound (using the same equipment), which is a routine examination.

This is a non-invasive, non-irradiating examination that has been proven to be safe. There are therefore no risks associated with the research.

The expected benefit is collective:

  • To determine the distribution of the VEXUS score among patients in the general intensive care unit.
  • To determine the feasibility of measuring the VEXUS score in the prone position.
  • To determine the evolution of the VEXUS score in the prone position.
  • To determine the correlation between the VEXUS score and femoral and popliteal venous flow.

In addition, the ultrasound protocol used could enable early diagnosis of venous thrombosis (suprahepatic, portal, renal, femoral or popliteal), thereby helping to improve patient care.

  • 3) DESCRIPTION OF THE POPULATION TO BE STUDIED All consecutive adult patients admitted to a medical intensive care unit (Besançon Teaching Hospital, Besançon, FRANCE).
  • 4) REFERENCES TO SCIENTIFIC LITERATURE: BIBLIOGRAPHY See "Citations" field in the "References" module of the record.
Being tested
Venous ultrasound (inferior vena cava, portal vein, suprahepatic vein, and renal vein to calculate the VEXUS score ; femoral vein and popliteal vein)
Keywords
VExUS score, venous congestion, femoral venous flow, popliteal venous flow
Medical subject headings
Hyperemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Venous ultrasound (inferior vena cava, portal vein, suprahepatic vein, and renal vein to calculate the VEXUS score ; femoral vein and popliteal vein)Procedure or surgery

    The research procedure consists of an abdominal venous ultrasound (inferior vena cava, portal vein, suprahepatic vein and renal vein) to calculate the VEXUS score, and a venous ultrasound of the lower limbs (femoral vein and popliteal vein). This procedure will be performed at the same time as the cardiac ultrasound (using the same equipment), which is a routine examination.

    This is a non-invasive, non-irradiating examination that has been proven to be safe. There are therefore no risks associated with the research.

Study groups in NCT07438015
Study groupRoleWhat they receive
Every adult patients admitted to a medical intensive care unit for any reasonExperimentalEvery adult patients admitted to a medical intensive care unit (Besançon Teaching Hospital, Besançon, FRANCE) for any reason.
Receives: Procedure: Venous ultrasound (inferior vena cava, portal vein, suprahepatic vein, and renal vein to calculate the VEXUS score ; femoral vein and popliteal vein)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Distribution of the VEXUS score among all patients admitted (for any reason) in a general intensive care unit

    Describe the distribution of the VEXUS score among all patients admitted (for any reason) in a general intensive care unit at Besançon Teaching Hospital (Besançon, city, FRANCE).

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

Secondary outcomes (9)
  1. Feasability of VEXUS score measurement in prone position

    • Assess the failure rate of the VEXUS score measurement in prone position (proportion of patients included in whom a VEXUS score value in prone position could not be obtained by the operator in less than 10 minutes).

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  2. Feasability of femoral venous flow measurement in supine and prone position

    • Assess the failure rate of femoral venous flow measurement in the supine position and in the prone positioning (proportion of patients included in whom femoral venous flow measurement in the supine position and the prone position could not be obtained by the operator in less than 10 minutes).

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  3. Feasability of popliteal venous flow measurement in supine and prone position

    • Assess the failure rate of popliteal venous flow measurement in the supine position and in prone positioning (proportion of patients included in whom popliteal venous flow measurement in the supine position and the prone position could not be obtained by the operator in less than 10 minutes).

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  4. VEXUS score evolution before, during and after prone positioning for ARDS

    • Describe the change in the VEXUS score (ranging from 0 (no congestion) to 3 (severe congestion)) before, during, and after the first prone position session in ARDS patients.

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  5. Femoral venous flow evolution before, during and after prone positioning for ARDS

    • Describe the evolution of femoral venous flow (laminar (no congestion), or biphasic (severe congestion)) before, during, and after the first prone position session in ARDS patients.

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  6. Popliteal venous flow evolution before, during and after prone positioning for ARDS

    Describe the evolution of popliteal venous flow (laminar (no congestion), or biphasic (severe congestion)) before, during, and after the first prone position session in ARDS patients.

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  7. Correlation between the VEXUS score and the pattern of femoral venous flow

    • Assess the correlation between the VEXUS score and the pattern of femoral venous flow (laminar of biphasic).

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  8. Correlation between the VEXUS score and popliteal venous flow pattern

    Assess the correlation between the VEXUS score and the pattern of popliteal venous flow (laminar of biphasic).

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

  9. Correlation between femoral and popliteal venous flow patterns

    • Assess the correlation between the pattern of femoral venous flow (laminar of biphasic) and the pattern of popliteal venous flow (laminar of biphasic).

    Measured: From the inclusion of the first patient to the 525th patient (approximately 9 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2026
  2. Study start12 Mar 2026
  3. Primary completion12 Mar 2027 (estimated)
  4. Study completion12 Mar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
525 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07438015
Sponsor's protocol ID
2025-A02033-46
Acronym
VEXUS-REA
Status last verified
Dec 2025
First submitted
29 Dec 2025
Last updated
27 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Andrei S, Bahr PA, Nguyen M, Bouhemad B, Guinot PG. Prevalence of systemic venous congestion assessed by Venous Excess Ultrasound Grading System (VExUS) and association with acute kidney injury in a general ICU cohort: a prospective multicentric study. Crit Care. 2023 Jun 8;27(1):224. doi: 10.1186/s13054-023-04524-4.

    PubMed 37291662
  • Zieleskiewicz L, Muller L, Lakhal K, Meresse Z, Arbelot C, Bertrand PM, Bouhemad B, Cholley B, Demory D, Duperret S, Duranteau J, Guervilly C, Hammad E, Ichai C, Jaber S, Langeron O, Lefrant JY, Mahjoub Y, Maury E, Meaudre E, Michel F, Muller M, Nafati C, Perbet S, Quintard H, Riu B, Vigne C, Chaumoitre K, Antonini F, Allaouchiche B, Martin C, Constantin JM, De Backer D, Leone M; CAR'Echo and AzuRea Collaborative Networks. Point-of-care ultrasound in intensive care units: assessment of 1073 procedures in a multicentric, prospective, observational study. Intensive Care Med. 2015 Sep;41(9):1638-47. doi: 10.1007/s00134-015-3952-5. Epub 2015 Jul 10.

    PubMed 26160727
  • Andrei S, Bahr PA, Alissant M, Saccu M, Nguyen M, Popescu BA, Bouhemad B, Guinot PG. Pulsatile Femoral Vein Doppler Pattern is a Parameter of Venous Congestion in ICU Patients. J Cardiothorac Vasc Anesth. 2024 Jun;38(6):1361-1368. doi: 10.1053/j.jvca.2023.04.028. Epub 2023 Apr 25.

    PubMed 38555215
  • Bhardwaj V, Rola P, Denault A, Vikneswaran G, Spiegel R. Femoral vein pulsatility: a simple tool for venous congestion assessment. Ultrasound J. 2023 May 10;15(1):24. doi: 10.1186/s13089-023-00321-w.

    PubMed 37165284
  • Grasselli G, Calfee CS, Camporota L, Poole D, Amato MBP, Antonelli M, Arabi YM, Baroncelli F, Beitler JR, Bellani G, Bellingan G, Blackwood B, Bos LDJ, Brochard L, Brodie D, Burns KEA, Combes A, D'Arrigo S, De Backer D, Demoule A, Einav S, Fan E, Ferguson ND, Frat JP, Gattinoni L, Guerin C, Herridge MS, Hodgson C, Hough CL, Jaber S, Juffermans NP, Karagiannidis C, Kesecioglu J, Kwizera A, Laffey JG, Mancebo J, Matthay MA, McAuley DF, Mercat A, Meyer NJ, Moss M, Munshi L, Myatra SN, Ng Gong M, Papazian L, Patel BK, Pellegrini M, Perner A, Pesenti A, Piquilloud L, Qiu H, Ranieri MV, Riviello E, Slutsky AS, Stapleton RD, Summers C, Thompson TB, Valente Barbas CS, Villar J, Ware LB, Weiss B, Zampieri FG, Azoulay E, Cecconi M; European Society of Intensive Care Medicine Taskforce on ARDS. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023 Jul;49(7):727-759. doi: 10.1007/s00134-023-07050-7. Epub 2023 Jun 16.

    PubMed 37326646
  • Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159-68. doi: 10.1056/NEJMoa1214103. Epub 2013 May 20.

    PubMed 23688302
  • Repesse X, Charron C, Vieillard-Baron A. Acute cor pulmonale in ARDS: rationale for protecting the right ventricle. Chest. 2015 Jan;147(1):259-265. doi: 10.1378/chest.14-0877.

    PubMed 25560864
  • Mekontso Dessap A, Boissier F, Charron C, Begot E, Repesse X, Legras A, Brun-Buisson C, Vignon P, Vieillard-Baron A. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Med. 2016 May;42(5):862-870. doi: 10.1007/s00134-015-4141-2. Epub 2015 Dec 9.

    PubMed 26650055
  • Viana-Rojas JA, Argaiz E, Robles-Ledesma M, Arias-Mendoza A, Najera-Rojas NA, Alonso-Bringas AP, De Los Rios-Arce LF, Armenta-Rodriguez J, Gopar-Nieto R, Briseno-De la Cruz JL, Gonzalez-Pacheco H, Sierra-Lara Martinez D, Gonzalez-Salido J, Lopez-Gil S, Araiza-Garaygordobil D. Venous excess ultrasound score and acute kidney injury in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2023 Jul 7;12(7):413-419. doi: 10.1093/ehjacc/zuad048.

    PubMed 37154067
  • Beaubien-Souligny W, Rola P, Haycock K, Bouchard J, Lamarche Y, Spiegel R, Denault AY. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system. Ultrasound J. 2020 Apr 9;12(1):16. doi: 10.1186/s13089-020-00163-w.

    PubMed 32270297
  • Beaubien-Souligny W, Benkreira A, Robillard P, Bouabdallaoui N, Chasse M, Desjardins G, Lamarche Y, White M, Bouchard J, Denault A. Alterations in Portal Vein Flow and Intrarenal Venous Flow Are Associated With Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Cohort Study. J Am Heart Assoc. 2018 Oct 2;7(19):e009961. doi: 10.1161/JAHA.118.009961.

    PubMed 30371304
  • Denault AY, Beaubien-Souligny W, Elmi-Sarabi M, Eljaiek R, El-Hamamsy I, Lamarche Y, Chronopoulos A, Lambert J, Bouchard J, Desjardins G. Clinical Significance of Portal Hypertension Diagnosed With Bedside Ultrasound After Cardiac Surgery. Anesth Analg. 2017 Apr;124(4):1109-1115. doi: 10.1213/ANE.0000000000001812.

    PubMed 28151822
  • Abu-Yousef MM, Kakish ME, Mufid M. Pulsatile venous Doppler flow in lower limbs: highly indicative of elevated right atrium pressure. AJR Am J Roentgenol. 1996 Oct;167(4):977-80. doi: 10.2214/ajr.167.4.8819397.

    PubMed 8819397
  • Alimoglu E, Erden A, Gursel K, Olcer T. Correlation of right atrial pressure and blood flow velocities in the common femoral vein obtained by duplex Doppler sonography. J Clin Ultrasound. 2001 Feb;29(2):87-91. doi: 10.1002/1097-0096(200102)29:23.0.CO;2-1.

    PubMed 11425093
  • Beaubien-Souligny W, Bouchard J, Desjardins G, Lamarche Y, Liszkowski M, Robillard P, Denault A. Extracardiac Signs of Fluid Overload in the Critically Ill Cardiac Patient: A Focused Evaluation Using Bedside Ultrasound. Can J Cardiol. 2017 Jan;33(1):88-100. doi: 10.1016/j.cjca.2016.08.012. Epub 2016 Aug 24.

    PubMed 27887762

Questions about this trial

What is this clinical trial studying?

A study testing Venous ultrasound (inferior vena cava, portal vein, suprahepatic vein, and renal vein to calculate the VEXUS score ; femoral vein and popliteal vein) in people with Venous Congestion, run by Centre Hospitalier Universitaire de Besancon at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hadrien WINISZEWSKI, MCU-PH (0033381668127, hwiniszewski@chu-besancon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Distribution of the VEXUS score among all patients admitted (for any reason) in a general intensive care unit (time frame: From the inclusion of the first patient to the 525th patient (approximately 9 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07438015, which also lists 39 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in